AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 27 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States have identified a novel method for treating latent Epstein-Barr virus infection.
"Epstein-Barr virus (EBV) is a human herpesvirus that establishes a lifelong latent infection in the majority of the human population," explained Lori Cooper and colleagues at Northwestern University Medical School in Chicago. "In normal individuals, latent infection with EBV typically poses no health risk, but upon immunosuppression, either following organ transplantation or HIV infection, malignancies and lymphoproliferative diseases can result."
EBV's latent membrane protein 2A (LMP2A) represents a novel therapeutic target, Cooper and coauthors found.
The researchers evaluated the antiviral efficacy of agents that block the function of kinases whose activity is affected by LMP2A. These include the Src family of protein tyrosine kinases, the Syk and Btk protein tyrosin kinases, and phosphatidylinositol 3-kinase, according to the report.
The Syk tyrosine kinase inhibitor piceatannol had a significant effect on cultured EBV-infected B cells, study data showed. Piceatannol treatment had no effect on uninfected B cells.